337O - The changes in the treatment of elderly AML patients in Korea: A single center experience
| Date | 19 December 2016 |
| Event | ESMO Asia 2016 Congress |
| Session | Haematological malignancies |
| Topics | Anticancer agents Leukaemia Geriatric Oncology |
| Presenter | Hyewon Ryu |
| Citation | Annals of Oncology (2016) 27 (suppl_9): ix104-ix111. 10.1093/annonc/mdw586 |
| Authors |
I. Song, Y.S. Choi, H. Ryu, S.W. Baek, J.Y. Moon, H.J. Lee, H.J. Yun, S. Kim, D.Y. Jo
|
Abstract
Background
Decitabine have been used widely in the elderly AML patients, since the National Health Insurance system started to cover it in the November 2013 in Korea. This study was conducted to review the changes of the treatment pattern and draw the better treatment strategies.
Methods
This study enrolled patients who were newly diagnosed with AML aged ≥65 years between 2010 and 2015 at Chungnam National University Hospital. The primary end point was overall survival, and the secondary end points were complete response (CR) rate, 1-year survival rate, and early mortality (death within 2 months).
Results
In total, 42 patients were diagnosed with AML from Jan. 2011 to Oct. 2013 and 26 patients from Nov. 2013 to Dec. 2015. After the insurance of decitabine, the patients were treated with any kind of chemotherapy more frequently than before (84.6% v 54.8%, respectively, p
Conclusions
These results indicate that decitabine is a reasonable treatment option in patients with age ≥70 years and WBC counts
Clinical trial indentification
Legal entity responsible for the study
Chungnam National University Hospital IRB
Funding
Chungnam National University Hospital
Disclosure
All authors have declared no conflicts of interest.